Red light has been shown to provide neuroprotective effects. Axotomizing the optic nerve initiates retinal ganglion cell (RGC) degeneration, and an early marker of this is dendritic pruning.
PBM showed visual acuity improvements and drusen reduction in dry AMD through multi-pathway mechanisms.
Mitochondrial dysfunction is common pathogenic feature across optic neuropathies; photobiomodulation offers enhancement without genetic manipulation.
Photobiomodulation (PBM), also known as low level laser therapy, has recently risen to the attention of the ophthalmology community as a promising new approach to treat a variety of retinal conditions including age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, Leber’s hereditary optic neuropathy, amblyopia, methanol-induced retinal damage, and possibly others.
LED-based photobiomodulation offers broader coverage, reduced thermal risk, and cost-effectiveness with clinical outcomes comparable to lasers across retinal diseases.
PBM showed consistent ATP enhancement, oxidative stress reduction, and visual improvements across retinal diseases with favorable safety profiles.
Myopia is one of the main causes of visual impairment worldwide. We conclude that red light irradiation can produce hyperopia, resulting in myopia prevention and control.
Real-time imaging showed 670 nm immediately increased mitochondrial electron transport within seconds, providing first direct visualization of PBM metabolic effects.
Evidence is growing that photobiomodulation (PBM) can restore the function of damaged mitochondria, upregulate the production of cytoprotective factors and prevent apoptotic cell death.
In the digital age, the widespread presence of electronic devices has exposed humans to an exceptional amount of blue light (BL) emitted from screens, LEDs, and other sources.
